4 DR Reddy

Recent Achievements : REUTERS - U.S. health regulators approved Indian drugmaker Dr Reddy's Laboratories' application to market generic version of AstraZeneca Plc's.

Dr Reddys Laboratories has been an outperformer and we are assuming that previous decline was a correction and it has just come out of a small trading range. As pharmaceuticals are outperforming after a correction DR Reddy is a buy on dips stock.

Buy DR Reddy in the range of 1631 to 1642 for a medium to long term target of 1685, 1715, 1815 with a stop loss of 1590.


4 comments:

  1. sure ..ill wait for this ..

    ReplyDelete
  2. DR Reddy is not moving. Please close this call and exit all your positions cost to cost.

    ReplyDelete
  3. Although we exited DR Reddy cost to cost but as expected all 1685 and 1715 targets done

    ReplyDelete
  4. Yesterday DRReddy touched 1810 high...we deadly missed this stock...

    ReplyDelete

Thanks for giving your valuable inputs, TRENDGURUS

OUR EXPERTISE

We provide expert in our field. Over 5+ years of experience we will ensure that you are always getting good guidance from the top people in the industry.

Thought of the day

"The man who has minted money with both hands in the Indian stock market says wealth is important but is not the source of all happiness.", Rakesh Jhunjhuwala

SUBSCRIBE US

Latest News

1) PM Modi fires back at the opposition, forcefully defend demonetisation 2) Nirav Modi to Stay in Jail for at least 28 more days.

By Using this website\Blog, you agree to the Disclaimer provided at Disclaimer -|- Designed by Tritan Solutions Pvt. Ltd -|- Copyright © 2019 -|- All rights reserved

ERP MLM Ecommerce Algo Software Development Company in Delhi | Digital Marketing | Algorithmic Trading | Ecommerce website